Clinical profile of McCune-Albright syndrome in Chinese pediatric patients: A single-center retrospective study

Some of the body's most complex instructions are written in a single strand of DNA, but sometimes a typo occurs not in the blueprint itself, but in a single copy of the instruction manual after the body has already begun to build. This is the nature of McCune-Albright syndrome, a rare condition where a specific genetic change happens randomly in some cells during early development, leaving others untouched. Because this change affects a protein that helps cells respond to signals, the cells that carry the mutation act as if they are receiving constant "go" orders, growing or functioning without the usual stop signs. This leads to a patchwork of symptoms that can appear in the skin, bones, and hormone-producing glands, making the condition difficult to predict and even harder to diagnose. For doctors, the challenge lies in recognizing that a child might have this syndrome even if they do not show the full set of classic signs, and for families, the journey often begins with unexplained early growth or unusual skin markings.

A team of researchers at Beijing Children's Hospital recently set out to map the landscape of this condition within their own community, looking back at the records of sixty-six children diagnosed with the syndrome over a decade. Their goal was to understand how this rare disorder actually presents in Chinese children, a group that had not been studied in large numbers before. By reviewing medical histories, genetic tests, and treatment outcomes, the team pieced together a clear picture of who gets sick, what symptoms appear first, and how the disease behaves differently in boys and girls. The study, which covers patients from infancy up to fifteen years old, reveals that while the condition is rare, its patterns are consistent enough to guide better care, provided doctors know what to look for.

The most striking finding from the hospital records is that the disease does not affect boys and girls in the same way. In this group of sixty-six children, there were fifty-six girls and only ten boys, a ratio that suggests the condition is far more visible in females. The primary reason for this imbalance appears to be the timing of diagnosis. Girls often show signs of early puberty, a condition where the body begins to mature sexually much sooner than normal, which brings them to the doctor's attention quickly. In contrast, boys in this study were much less likely to have early puberty, with only two out of ten showing the symptom. Instead, boys were more likely to present with bone problems, specifically a condition where normal bone is replaced by weaker, fibrous tissue that can lead to pain or fractures. While nearly all the girls in the study had early puberty, less than half of the boys did, and conversely, the bone condition was found in ninety percent of the boys but only about half of the girls. This difference highlights how the same genetic error can manifest differently depending on the patient, often leading to a delay in diagnosis for boys who do not show the most obvious hormonal signs.

Beyond the gender divide, the study confirmed that the classic set of three symptoms often taught in medical textbooks is actually the exception rather than the rule. The textbook description of the syndrome includes three specific features: a distinctive type of skin pigmentation that looks like a stain of coffee with milk, the bone weakness mentioned earlier, and early puberty. However, in this group of children, only about one in five patients had all three of these features at the same time. The vast majority presented with just two of the features, or sometimes just one. This is a crucial detail for clinicians, as it means that waiting for the full trio of symptoms to appear could mean missing the diagnosis entirely. The most common sign seen across the board was the skin pigmentation, which appeared in eighty-five percent of the children, followed closely by early puberty. The bone condition was present in just over half the group. Because the symptoms are so varied, the researchers emphasize that a doctor should suspect the syndrome if a child has even a single one of these major signs, especially if it is accompanied by other unexplained hormonal or skeletal issues.

The study also shed light on the difficulty of finding the genetic cause of the disease through standard blood tests. The mutation responsible for McCune-Albright syndrome is a mosaic, meaning it exists only in certain parts of the body and not in others. When the researchers tested the blood of eighteen children, they found the genetic change in only one of them. However, when they were able to test tissue taken directly from the affected areas, such as bone or adrenal glands, the mutation was found in every single sample. This suggests that for this specific condition, a blood test is often not enough to confirm the diagnosis. The genetic error is simply too diluted in the blood to be seen by standard methods, but it is abundant in the tissues where the disease is active. This finding supports a shift in how doctors might approach testing, prioritizing samples from the affected site whenever possible to get a definitive answer.

Treatment in this group of children focused on managing the specific symptoms that caused the most distress. For the girls with early puberty, doctors used medications to either block the production of sex hormones or to stop the ovaries from releasing cysts that drive the process. In some cases, surgery was required to remove large ovarian cysts that had twisted or caused pain. For the children with bone issues, the treatment involved medications that help strengthen the bone and reduce pain, though the researchers noted that these drugs are not a cure and must be used carefully. One particularly severe case involved two infants who were born with dangerously high levels of stress hormones, a condition that required surgical removal of part of their adrenal glands to survive. These varied treatments underscore that there is no single pill for McCune-Albright syndrome; care must be tailored to the specific problems each child faces, from the skin to the skeleton to the hormones.

The researchers concluded that while the clinical picture of McCune-Albright syndrome in Chinese children closely mirrors what has been seen in Western countries, the specific mix of symptoms and the age at which they appear offer new insights. The study confirms that the condition is a mosaic of possibilities, where the timing of the genetic error during development dictates which parts of the body are affected. It also serves as a reminder that the classic textbook definition of a disease is often too narrow for real-world practice. By documenting the experiences of these sixty-six children, the team has provided a clearer roadmap for doctors to follow, emphasizing that early recognition of incomplete symptoms and the use of targeted tissue testing are essential for helping these children grow and thrive. The work does not solve the mystery of the syndrome, but it brings the medical community closer to understanding how to navigate its complexities with confidence and care.